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b-Thallassemia is an inherited disorder of haemoglo-
bin synthesis, resulting in chronic haemolytic anemia.
Adequate blood transfusions and continuous chelation
therapy are the milestones of treatment. In adults, the
major haemoglobin is haemoglobin A, a tetramer
consisting of one pair of a chains and one pair of b
chains. Normally the ratio of a to b chains is one. In
patients with thallassemia production of b chains is
diminished. The excess a chains are unstable and
incapable of forming soluble teramers. These chains
precipitate in the cell, leading to a variety of clinical
manifestations [1]. Thallassemias arise from over 100
mutations, that affect every step for production of
normal haemoglobin. The frequency for genetic
abnormalities associated with b-thallassemia
approaches 0.1 in South Mediterranean areas in
Europe. Both sexes are equally affected [2]. The b-
thallassemia syndromes are remarkable for their
heterogeneity and clinical expression of the genetic
abnormality [3]. Patients with a b-thallassemia muta-
tion on each chromosome usually exhibit some degree
of a-globin inclusion body formation, with
consequent anemia, hemolysis and varying degrees
of ineffective erythropoiesis [1]. The clinical syn-
drome associated with this genetic disorder is called
thallassemia major. Patients, who are heterozygotes
for b-thallassemia are mostly asymptomatic. This,
because the erythrocyte is able to catabolize some of
the excess unpaired a-globulin chains [1]. The syn-
drome is usually described as thallassemia minor or
thallassemia intermediate. In patients with b-thallass-
emia major cardiac abnormalities occur frequently
next to disorders of the liver and spleen, skeletal
abnormalities and kidney and endocrine abnormalities
[4]. Heart failure and rhythm disturbances are the
main cause of death in adults with thallassemia major.
In a recently published multicenter study 5% of
patients aged 16–24 years and 23% of patients older
than 25 years had heart disease requiring medication
[5]. In another study congestive heart failure was
observed in 5.4% of patients with thallassemia
intermedia. Eight percent of these patients had a
history of acute pericarditis [4]. The most prominent
finding in patients with thallassemia major is left
ventricular dysfunction, which is mainly due to severe
anemia and iron overload because of the regular blood
transfusions required to avoid hypoxia [6].
The estimation of iron stores in the heart would be
very helpful in order to evaluate the efficacy of
chelation therapy and determine the cardiac risk.
Although the iron storage proteins like hemosiderin
and ferritin are mostly intracellular, serum ferritin is
highly correlated with the amount of iron deposition
L. H. B. Baur (&)
Department of Cardiology, Atrium Medical Centre
Parkstad, University of Maastricht, Maastricht,
The Netherlands
e-mail: lbr01@atriummc.nl
L. H. B. Baur
Department of Cardiology, University of Maastricht,
Henri Dunantstreet 5, Heerlen, 6401 CX, The Netherlands
123
Int J Cardiovasc Imaging (2008) 24:855–856
DOI 10.1007/s10554-008-9349-6
and can therefore used as an index for intracardiac
iron load [7]. However, ferritin levels can be affected
by factors as fever or inflammation [8].
Therefore non-invasive guidance of cardiac iron
loading with T2* magnetic resonance imaging is a
better technique evaluate chelation therapy in patients
with thallassemia major [9].
Iron deposition results in shortening of proton
relaxation times, which can be used to assess
myocardial iron overload [10]. T2 relaxation time
has a linear correlation with the total iron content in
the heart [11] The current paper of Mavrogeni et al.
shows, that T2* imaging is able to differentiate
between thallassemia major and thallassemia inter-
mediate [12]. The T2* values of patients with
thallassemia major were half the value of patients
with thallassemia intermediate and normal individu-
als. Also right and left ventricular volumes and right
and left ventricular ejection fraction were higher in
the thallassemia intermediate patients compared to
the patients with thallassemia major. This despite
equal ferritin levels in both groups. These findings are
important, because the current study of Mavrogeni
et al. shows, that MRI with T2* imaging is a far more
sensitive technique to detect cardiac iron load than
measurement of serum ferritin. Although echocardi-
ography with tissue velocity imaging is able to detect
early ventricular function and ventricular dilation in
thallassemia patients it does not detect cardiac iron
load [13].
Therefore cardiac magnetic resonance imaging is
the preferred technique to image iron load in the
myocardium in patients with thallassemia and guide
chelation therapy.
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